Form 4: Ultragenyx CFO Howard Horn Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Ultragenyx Pharmaceutical's CFO, Howard Horn, sold 1,785 shares of common stock on March 6, 2025, to cover tax withholdings related to vesting RSUs.
Summary
- On March 6, 2025, Howard Horn, the Chief Financial Officer of Ultragenyx Pharmaceutical Inc., sold 1,785 shares of common stock.
- The sale was executed at a weighted average price of $40.4 per share, with individual transactions ranging from $39.73 to $41.37.
- The purpose of the sale was to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
- Following the transaction, Horn still beneficially owns 106,169 shares, which includes previously reported shares of common stock underlying RSUs subject to vesting conditions.
Sentiment
Score: 5
Explanation: This is a neutral event. The sale is related to tax obligations and doesn't necessarily indicate a negative outlook on the company.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This sale appears to be a standard transaction to cover tax obligations related to equity compensation.
Stakeholder Impact
- The sale is unlikely to have a significant impact on shareholders, as it is a relatively small transaction by an insider to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of the stock sale transaction. |
| 03/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.